Minakem Header W48

Minakem Header W48

X

[{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Kennedy Krieger Institute","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ORYZON Starts Preclinical Collaboration on Kabuki Syndrome with Kennedy Krieger Institute and Johns Hopkins University","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"SPAIN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Oryzon Genomics"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"CMT Research Foundation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ORYZON Collaborates with the CMT Research Foundation in the US","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"SPAIN","productType":"Small molecule","productStatus":"Undisclosed","date":"July 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Oryzon Genomics"},{"orgOrder":0,"company":"SOM Biotech","sponsor":"University of Minnesota","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"SOM Biotech Signs Licensing Agreement With the University of Minnesota","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"SPAIN","productType":"Small molecule","productStatus":"Undisclosed","date":"May 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"SOM Biotech"},{"orgOrder":0,"company":"ARTHEx Biotech","sponsor":"EIC Accelerator","pharmaFlowCategory":"D","amount":"$13.7 million","upfrontCash":"Undisclosed","newsHeadline":"Arthex Biotech Selected for EIC Accelerator Award of up to 14 Million Euros","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"SPAIN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"ARTHEx Biotech"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

ARTHEx Biotech

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Arthex Biotech Selected for EIC Accelerator Award of up to 14 Million Euros

Details:

Proceeds will be used to fund the FIGHT-DM 1 project to initiate clinical trial of Arthex' lead candidate, ATX-01, in DM1 in 2023.

Lead Product(s): ATX-01

Therapeutic Area: Genetic Disease Product Name: ATX-01

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: EIC Accelerator

Deal Size: $13.7 million Upfront Cash: Undisclosed

Deal Type: Funding October 25, 2022

ASK
US

Upload
your Pipeline Activity

Oryzon Genomics

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

ORYZON Collaborates with the CMT Research Foundation in the US

Details:

Under this collaboration, CMTRF will be financing a series of in vivo tests with Oryzon’s HDAC6 candidates in a murine model of CMT1A, which reliably recapitulates many of the symptoms of this condition in humans.

Lead Product(s): Undisclosed

Therapeutic Area: Genetic Disease Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: CMT Research Foundation

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration July 26, 2022

ASK
US

Upload
your Pipeline Activity

SOM Biotech

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

SOM Biotech Signs Licensing Agreement With the University of Minnesota

Details:

This agreement follows the completion of research agreement, in which the University of Minnesota conducted a series of in vitro studies on potential pre-clinical product candidates for Duchenne and Becker muscular dystrophy identified using SOM Biotech’s platform, SOMAIPRO.

Lead Product(s): Undisclosed

Therapeutic Area: Genetic Disease Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: University of Minnesota

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement May 17, 2022

ASK
US

Upload
your Pipeline Activity

Oryzon Genomics

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

ORYZON Starts Preclinical Collaboration on Kabuki Syndrome with Kennedy Krieger Institute and Johns Hopkins University

Details:

Vafidemstat (ORY-2001) is an oral, CNS optimized LSD1 inhibitor. The molecule acts on several levels: it reduces cognitive impairment, including memory loss and neuroinflammation, and at the same time has neuroprotective effects.

Lead Product(s): Vafidemstat

Therapeutic Area: Genetic Disease Product Name: ORY-2001

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: Kennedy Krieger Institute

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration May 03, 2022

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY